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Abstract
Introduction: The rationale of mesenchymal stem cells (MSCs) 
as a novel therapeutic approach in certain neurodegenerative 
diseases is based on their ability to promote neurogenesis. 
Hippocampal atrophy has been related to bipolar disorder (BD) 
in preclinical, imaging and postmortem studies. Therefore, the 
development of new strategies to stimulate the neurogenesis 
process in BD is crucial. 
Objectives: To investigate the behavioral and neurochemical 
changes induced by transplantation of MSCs in a model of mania-
like behavior induced by lisdexamfetamine dimesylate (LDX).
Methods: Wistar rats (n=65) received one oral daily dose of LDX 
(10 mg/kg) or saline for 14 days. On the 8th day of treatment, the 
animals additionally received intrahippocampal saline or MSC (1 
µL containing 25,000 cells) or lithium (47.5 mg/kg) as an internal 
experimental control. Two hours after the last administration, 
behavioral and neurochemical analyses were performed.
Results: LDX-treated rats had increased locomotor activity 
compared to saline-saline rats (p=0.004), and lithium reversed 
LDX-related hyperactive behavior (p<0.001). In contrast, 
the administration of MSCs did not change hyperlocomotion, 
indicating no effects of this treatment on LDX-treated rats 
(p=0.979). We did not find differences between groups in BDNF 
levels (p>0.05) in the hippocampus of rats. 
Conclusion: Even though these results suggest that a single 
intrahippocampal injection of MSCs was not helpful to treat 
hyperactivity induced by LDX and neither influenced BDNF 
secretion, we cannot rule out the possible therapeutic effects of 
MSCs. Further research is required to determine direct effects 
of LDX on brain structures as well as in other pathophysiological 
targets related to BD. 
Keywords: Mesenchymal stem cells, cellular therapy, bipolar 
disorder, mania, neurogenesis, hippocampus. 
Resumo
Introdução: Células-tronco mesenquimais (CTMs) têm 
emergido como um promissor tratamento em diversas doenças 
neurodegenerativas devido a sua plasticidade e capacidade 
de regenerar tecidos. Estudos pré-clínicos, clínicos e de 
neuroimagem têm demonstrado a presença de atrofia hipocampal 
no transtorno bipolar (TB). Portanto, o desenvolvimento de 
tratamentos capazes de regenerar tecido lesado e estimular a 
neurogênese poderia ser útil.
Objetivos: Investigar mudanças comportamentais e 
neuroquímicas induzidas pelo transplante de CTMs no hipocampo 
de ratos em um modelo animal de mania induzido por dimesilato 
de lisdexanfetamina (LDX).
Métodos: Ratos Wistar (n=65) receberam LDX (10 mg/kg) ou 
solução salina por via oral durante 14 dias. No oitavo dia, os 
animais foram transplantados com injeção de CTMs ou solução 
salina (1 µL contendo 25.000 células) ou lítio (47,5 mg/kg) como 
controle interno do experimento. Duas horas após a última dose, 
foram realizadas análises comportamentais e neuroquímicas.
Resultados: Animais que receberam LDX tiveram um aumento da 
atividade locomotora comparados ao grupo que recebeu solução 
salina (p=0,004); já o lítio reverteu a hiperatividade locomotora 
desses animais (p<0,001). Os animais que receberam CTMs não 
apresentaram alterações no comportamento, indicando ausência 
de efeitos sobre hiperatividade locomotora. Os níveis de BDNF 
hipocampais não diferiram entre os grupos (p>0.05). 
Conclusão: Não foi possível demonstrar efeitos neuroprotetores 
das CTMs, administradas em dose única, em um modelo animal 
de mania induzido por LDX. No entanto, não se pode descartar 
os possíveis efeitos terapêuticos das CTMs. Mais estudos são 
necessários para determinar os efeitos das CTMs em estruturas 
cerebrais e outros alvos fisiopatológicos relacionados ao TB.
Descritores: Células mesenquimais, terapia celular, transtorno 
bipolar, mania, neurogênese, hipocampo. 
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Introduction
Bipolar disorder (BD) is a chronic, recurrent and 
disabling mental illness. Although current treatments 
used for BD can relieve mood symptoms, they do not 
cure. Furthermore, relapse is always a risk.1 Therefore, 
it is essential to develop more effective therapeutic 
approaches to treat BD. 
Mesenchymal stem cells (MSCs) are self-renewing 
multipotent progenitor cells that have the capacity of 
differentiating into all lineages of mesodermal origin 
and non-skeletal cell types, including neurons.2-4 They 
exhibit the ability to migrate to injured sites, and 
this mechanism involves the expression of specific 
receptors to facilitate reaching the target site, adhering 
to and infiltrating the damaged tissue.2-4 Moreover, the 
therapeutic effectiveness of MSCs depends on their 
ability to secrete trophic factors that can stimulate 
the surrounding microenvironment and promote the 
regeneration of endogenous cells. In particular, MSCs 
produce brain-derived neurotrophic factor (BDNF), an 
important protein that stimulates neuroplasticity and 
neurogenesis in the hippocampus.2-4
Neurogenesis, the process by which new neurons are 
generated from neural stem cells, is continuous in the 
adult brain and essential for the maintenance of plasticity 
and cognitive function.3-6 An increasing body of evidence 
links impairment in hippocampal neurogenesis to BD.2 
For instance, a sample of individuals with euthymic BD-I 
disorder revealed significantly smaller left hippocampal 
volume in BD-I patients compared with healthy controls, 
with shape analysis revealing specific reductions in the 
anterior head and medial border of the left hippocampus.7 
Another neuroimaging study examined the effect of the 
BDNF val66met genotype on hippocampal volumes in 
patients with mood disorders, showing a strong association 
between the BDNF val66met polymorphism and reduced 
hippocampal volumes in BD-I patients.8 Serum BDNF 
levels are also decreased in manic and depressed bipolar 
patients in comparison with euthymic and healthy 
controls.9 Furthermore, lithium, a mood-stabilizer 
used for the treatment of BD, exerts trophic actions on 
hippocampus, as an increase in total hippocampal volume 
has been found in patients exposed to lithium compared 
to those who did not receive this therapy.10 
Considering that BD is associated with hippocampal 
atrophy, the development of novel therapeutic strategies 
to stimulate neurogenesis is crucial. The rationale of 
MSCs as an alternative treatment of BD is based on their 
differentiation potential and migratory properties that 
enable tissue replacement. The aim of the present study 
was to investigate the behavioral and neurochemical 
changes induced by stereotaxic transplantation of 
MSCs in a model of mania-like behavior induced by 
lisdexamfetamine dimesylate (LDX). 
Materials and methods
Ethical approval
This study was approved by the institutional 
ethics committee and performed in accordance with 
Brazilian and international guidelines for animal 
experimentation.11
Isolation and culture of mouse adipose-derived MSC 
Epidydimal fat from male C57BL/6 mice was 
aseptically removed and enzymatically digested with 
1 mg/mL of collagenase type Ι (Sigma, St. Louis, 
MO, United States). Obtained cell suspensions were 
maintained in Dulbecco’s modified eagle medium 
(DMEM) with 200 mL/L fetal bovine serum (FBS) 
(Gibco, Carlsbad, CA, United States) and 100 units/mL 
penicillin and 100 mg/mL streptomycin (Gibco). They 
were incubated at 37 ºC in a humidified atmosphere 
containing 50 mL/L CO2. Adherent cells achieving 
80% confluence were split using 2.5 mL/L trypsin-
ethylenediaminetetraacetic acid solution (Gibco) and 
maintained in DMEM supplemented with 200 mL/L FBS 
and 1% of an antibiotic solution. In vivo administered 
MSCs were used between passages 3-6.
In parallel, MSC characterization experiments were 
performed by in vitro differentiation and immunophenotyping 
analysis according to Schneider et al.12
Animal model of mania-like behavior and cell 
transplantation
We used a model of mania-like behavior induced by LDX 
as previously described in Macêdo et al.13 The experiments 
were performed in adult male Wistar rats (aged 60 days) 
obtained from the Animal House of Universidade Federal 
do Rio Grande do Sul. Animals were divided into six groups 
of 9-12 each (n=65). Each group of animals received one 
oral daily dose of LDX (10 mg/kg) or saline for 14 days. 
On the 8th day of treatment, the animals additionally 
received saline (1 µL, intrahippocampal injection) or MSC 
(1 µL containing 25,000 cells, intrahippocampal injection). 
Additionally, a group of animals received lithium (47.5 
mg/kg, intraperitoneal injection, twice a day) as an 
internal (positive) experimental control. All animals were 
maintained on a 12-hour light-dark cycle and received 
water and food ad libitum. 
Surgery
Animals were implanted with bilateral 14-mm or 9.0-
mm, 23-gauge guide cannulae aimed 1.0 mm above the 
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CA1 area of the dorsal hippocampus, under anesthesia 
with ketamine (75 mg/kg) and xylazine (25 mg/kg). 
Coordinates (were obtained from the atlas of Paxinos 
& Watson14 (anteroposterior, -4.3 mm from bregma; 
mediolateral, ±3.0 mm from bregma; ventral, -2.0 mm 
from skull surface). Animals were allowed to recover for 
at least five days after surgery.
Open-field test
Spontaneous locomotor activity was evaluated in 
an open field apparatus which consisted of a circular 
arena (78 cm in diameter and 36 cm-high walls) with 
an open top and a dark floor divided into 25 spaces. 
Animals were gently placed in the arena for 15 min, 
and each test was recorded with a digital camera. After 
each individual animal test, the apparatus was cleaned 
with a 70% alcohol solution. To evaluate locomotion, 
the number of lines crossed, distance travelled (m), 
average speed (m/s) and the number of rearings 
were analyzed. After this task, rats were sacrificed by 
decapitation, and brain tissue was prepared and used 
for determination of BDNF levels. 
Measurement of hippocampal BDNF levels 
The levels of BDNF were determined in each sample 
by enzyme immunoassays (ELISA; Millipore, USA) 
according to the manufacturer’s instructions.
Results
To explore the effects of MSC on mania-like animal 
model locomotor activity was assessed two hours after 
the last LDX injection (Figure 1). In this study, two-way 
ANOVA of number of crossings showed a significant 
interaction between LDX protocol and treatment groups 
(F2=3.913, p=0.026) with a significant main effect of 
LDX protocol (F1=27.494, p<0.001) and treatment 
groups (F2=33.623, p<0.001). As expected, LDX-treated 
rats had increased locomotor activity compared to 
saline-saline rats (p=0.004), and lithium reversed LDX-
related hyperactive behavior (p<0.001). In contrast, the 
administration of MSCs did not change hyperlocomotion, 
indicating no effects of this treatment on LDX-treated 
rats (p=0.979).
Figure 1 - Effect of MSC injection on spontaneous locomotor activity of LDX-treated rats in the open field. Exploratory activities such as 
frequency of crossings (A), distance travelled (B) and average speed (C) were increased in LDX+Sal and LDX+MSC groups, compared 
to Sal+Sal and Sal+MSC, while lithium reduced these parameters. Regarding the frequency of rearings (D), the LDX+MSC group 
exhibited a more exploratory behavior than Sal+Sal and Sal+MSC, and treatment with lithium reduced this frequency, as expected. 
All data were analyzed by one-way ANOVA followed by Tukey’s post hoc. Results expressed as mean ± standard deviation. * p<0.05 
compared to Sal+Sal; † p<0.05 compared to Sal+MSC; ‡ p<0.001 compared to LDX+Sal; and § p<0.001 compared to LDX+MSC. LDX = 
lisdexamfetamine; MSC = mesenchymal stem cell; Sal = saline.
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Regarding rearing behavior, there was also a significant 
interaction between both factors (F=12.099, p<0.001), 
with significant main effects of treatment groups 
(F=21.972, p<0.001) and a trend effect of LDX protocol 
(F=3.608, p=0.063). Post hoc analysis showed increased 
rearing behavior in LDX-treated rats compared to saline-
saline rats (p<0.001); however, these effects were not 
reversed by MSCs (p=0.947) or lithium (p=0.207). 
With regards to distance, significant main effects 
of LDX protocol (F1=33.390, p<0.001) and treatment 
groups (F2=33.558, p<0.001) were observed. Post hoc 
analysis showed increased distance of LDX-treated rats 
compared to controls (p<0.001), and lithium reversed 
such effects. The administration of MSCs did not change 
this behavior (p=0.944). 
Furthermore, we found differences in hippocampal 
BDNF levels between the groups (F=2.661, p=0.046). 
However, there were no intergroup differences in the post 
hoc analysis. A non-significant trend for LDX+lithium 
was observed when this group was compared to Sal+Sal 
(p=0.094), while no differences were found between 
LDX+lithium and LDX+Sal (p=0.864). 
Discussion
This is the first study to treat LDX-induced mania-like 
behavior with intrahippocampal transplantation of MSCs. 
We hypothesized that MSCs would improve behavioral 
function, perhaps emerging as a useful strategy to treat 
psychiatric disorders. However, our results suggest that a 
single intrahippocampal injection of MSCs, at a particular 
time-point of a behavioral study, did not reverse a specific 
mania-like behavior or influence BDNF levels. 
Some preclinical studies have revealed effects of 
MSCs in various CNS diseases, showing positive results 
(see Table 1). However, most of these studies focused 
on neurodegenerative diseases, which are characterized 
by injury to a particular area of the brain. In Parkinson’s 
disease, for instance, the loss of dopaminergic neurons 
occurs mainly in the substantia nigra. In this case, MSCs 
may migrate to this region and promote tissue regeneration 
through their immunomodulatory properties and secretion 
of trophic factors. In contrast, BD is characterized by 
dysfunctions in distinct areas of the brain, particularly 
in the prefrontal-striatal-pallidal-thalamic-limbic brain 
networks.20 Furthermore, the animal model of mania-
like behavior induced by LDX causes redox alterations in 
specific brain areas (hippocampus, prefrontal cortex and 
striatum). Therefore, it is possible to speculate that the 
absence of MSC effects in the present study is due to the 
characteristics of bipolar illness. In particular, the damage 
in BD seems to extend to distinct areas of the brain, 
thereby diluting the regeneration potential of MSCs. 
Furthermore, the route, number of cell doses, time and 
frequency of MSC administration is critical. In our study, 
Table 1 - Effects of MSCs in various CNS diseases
CNS disease 
(reference)
Experimental 
model MSC source Dose Site of injection Characteristic
Parkinson15 6-OHDA-treated 
Wistar rats
hMSCs 
rMSCs
1x105 cells Intrastriatal ↑ Dopaminergic cells
Parkinson16 LPS challenged 
Sprague-Dawley rats 
and MPTP-treated 
C57BL/6 mice
hMSCs 1x106 cells
1x105 cells
Intravenous ↓ TH neuronal loss
↓ Activation of microglia and 
inflammatory markers
Depression6 Flinders sensitive line 
rats
rMSCs 1x105 cells Intracerebroventricular ↑ Neural markers 
Hippocampal neurogenesis
Behavior improvement
Depression and 
anxiety3
Lewis rats Lewis rMSCs 3x103 cells Intrahippocampal ↑ Neurogenesis 
No alteration in behavioral functions
Spinal cord 
injury17
Spinal cord injured 
Sprague-Dawley rats
Bone marrow 
of Sprague-
Dawley rats
1x106 cells Intravenous ↑ Locomotor function
Remyelination of axons in the 
perilesional region
Microvessel formation
Traumatic brain 
injury18
Traumatic brain 
injured Wistar rats
hMSCs 1x106 cells Intravenous ↑ Sucrose preference
↑ Working memory
Parkinson19 6-OHDA-treated 
Sprague-Dawley rats
MSCs of bone 
marrow of 
C57BL/6-Tg
1x106 cells
3x105 cells
Intranasal ↑ TH activity and BDNF
↓ IL-2, IL-6, TNF-α, IFN-γ and GM-
CSF
CNS = central nervous system; MSC = mesenchymal stem cell; 6-OHDA = 6-hydroxydopamine; hMSCs = human mesenchymal stem cells; rMSCs = rat 
mesenchymal stem cells; LPS = lipopolysaccharide; MPTP = 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; TH = tyrosine hydroxylase; BDNF = brain-derived 
neurotrophic factor; IL = interleukin; TNF-α = tumor necrosis factor α; IFN-γ = interferon γ; GM-CSF = granulocyte-macrophage colony-stimulating factor.
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we injected one dose of MSC into the hippocampus on 
the 8th experimental day. Despite the scarce literature, 
it has been suggested that the gene expression of factors 
involved in hippocampal proliferation would increase 
over a period of seven days. However, Coquery et al.3 
suggested that changes in the secretion of these factors 
as well as changes in behavioral outcomes take longer 
than seven days to occur. Alterations in neurogenesis 
may occur after two weeks of left intra-cerebroventricular 
injection of MSCs,6 and 50 days after intra-hippocampal 
injection of MSCs.3 All these data would serve as a 
theoretical basis for the negative findings of our study, 
leading to the rationale that the seven-day period is not 
sufficient to promote significant changes in hippocampal 
structural plasticity and behavioral outcomes. 
Although the local injection of MSCs is the most 
accepted method, it could cause an increase in pressure 
and bleed on the microstructures that receive these 
cells. This fact, in turn, may trigger a potentiation of 
local inflammatory signals and a reaction against the 
cell graft.21 If this is the case, BDNF secretion may have 
been affected by this acute inflammation or even by the 
cell death transplanted into the site. In this context, 
some authors have suggested the intracerebrospinal 
or intracerebroventricular routes as alternative delivery 
methods. Although the administration of MSC injection 
into the cerebrospinal fluid could solve this issue, the 
amount of cells that reach the target and the inefficient 
migration of MSCs to the injury may also limit their 
therapeutic effects.22 Methodological differences regarding 
the time and frequency of cell administration and the 
amount of cells transplanted may have contributed to 
the discrepancies between results. Finally, in addition 
to previous observations, the histological validation 
that MSCs are thriving in vivo after their hippocampal 
administration is critical to understand the role of MScs 
on hippocampal neurogenesis as well as the effects of 
MSCs on behavior. This limitation may be directly involved 
with the results observed in the behavior of animals and 
should be analyzed in future studies.
Psychostimulant-induced models of mania have 
been used as a preclinical tool (with adequate face, 
construct and predictive validity) for the assessment 
of novel therapeutic strategies in the treatment of 
BD.23 The animal model of mania induced by LDX, 
for instance, showed oxidative stress abnormalities 
and hyperlocomotion in rats, and both alterations 
were reversed by lithium.13 However, it is plausible 
to consider that mania-like behavior induced by LDX 
does not promote some biological changes found in 
BD, in particular, inflammatory changes and BDNF 
alterations, which are also potential targets of MSCs. 
Also, the lack of assessment of hippocampal volume in 
the LDX model should be considered when interpreting 
the present results. Future studies should evaluate 
hippocampal atrophy in the LDX model of mania-like 
behavior through the use of 5-bromo-2’-deoxyuridine 
and dendritic branching by a simple Sholl analysis to 
validate the presence of decreased proliferation in 
hippocampal tissue or atrophy in this animal model. 
Finally, due to the complexity of BD, other behavioral 
measures such as goal-directed behavior, circadian 
patterns and feeding should have been considered. It is 
important to point out that all the outcomes mentioned 
above are crucial for the elaboration of a clear idea 
about the role of LDX in hippocampal structures and 
behavioral changes in this mania-like model. 
Despite the limitations discussed above, this is the 
first study to assess cellular therapy for the treatment 
of BD. It is important to note that, even though there 
was no reversal of hyperlocomotion or BDNF secretion, 
we cannot rule out the possible therapeutic effects 
of MSCs. Future experiments are needed to establish 
validity parameters for this animal model and determine 
direct LDX effects in brain structures as well as in 
other pathophysiological targets related to BD (e.g., 
inflammatory markers and neurotrophic factors). 
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